COVID-19 in diabetic patients: related risks and specifics of management.
COVID-19 in diabetic patients: related risks and specifics of management.
Ann Endocrinol (Paris). 2020 May 12;:
Authors: Orioli L, Hermans MP, Thissen JP, Maiter D, Vandeleene B, Yombi JC
Abstract
Diabetes is among the most frequently reported comorbidities in patients infected with COVID-19. According to current data, diabetic patients do not appear to be at increased risk of contracting SARS-CoV-2 compared to the general population. On the other hand, diabetes is a risk factor for developing severe and critical forms of COVID-19, the latter requiring admission to an intensive care unit and/or use of invasive mechanical ventilation, with high mortality rates. The characteristics of diabetic patients at risk for developing severe and critical forms of COVID-19, as well as the prognostic impact of diabetes on the course of COVID-19, are under current investigation. Obesity, the main risk factor for incident type 2 diabetes, is more common in patients with critical forms of COVID-19 requiring invasive mechanical ventilation. On the other hand, COVID-19 is usually associated with poor glycemic control and a higher risk of ketoacidosis in diabetic patients. There are currently no recommendations in favor of discontinuing antihypertensive medications that interact with the renin-angiotensin-aldosterone system. Metformin and SGLT2 inhibitors should be discontinued in patients with severe forms of COVID-19 owing to the risks of lactic acido...
Source: Annales d'Endocrinologie - Category: Endocrinology Authors: Orioli L, Hermans MP, Thissen JP, Maiter D, Vandeleene B, Yombi JC Tags: Ann Endocrinol (Paris) Source Type: research
More News: COVID-19 | Diabetes | Diabetes Type 2 | Eating Disorders & Weight Management | Endocrinology | Fortamet | Intensive Care | Metformin | Obesity | SARS | SGLT2 Inhibitors